QL2107

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Patients With Advanced Solid TumorsEfficacyAdenocarcinomaBiliary Tract CancerAdvanced Solid Tumor

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

1

Keytruda

Merck & Co.

Phase 2

192

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

153

Lazcluze

Johnson & Johnson

Phase 2

14

Tuoyi

CCoherus Oncology, Inc.

Phase 2

95

Cyramza

Eli Lilly

Phase 2

16

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

67

QL2107

Qilu Pharmaceutical Co., Ltd.

Phase 3

18

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

19

Albumin-Bound Paclitaxel

Bristol-Myers Squibb

Phase 2

210

Carboplatin AUC-5

Merck & Co.

Phase 2

1Show 32 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Advanced Solid Tumor1 trial

A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

Recruiting·Qilu Pharmaceutical Co., Ltd.·Phase 1/2·NCT06911827·90 enrolled

Patients With Advanced Solid Tumors1 trial

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

Recruiting·Qilu Pharmaceutical Co., Ltd.·Phase 1/2·NCT07256782·444 enrolled

Adult1 trial

A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults

Unknown status·Qilu Pharmaceutical Co., Ltd.·Phase 1·NCT06173011·168 enrolled

Efficacy1 trial

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Recruiting·Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT06754644·808 enrolled

Biliary Tract Cancer1 trial

Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract Cancer

Not yet recruiting·Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT07151872·120 enrolled

3 more indications

Adenocarcinoma1 trial

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Not yet recruiting·Qilu Pharmaceutical Co., Ltd.·Phase 2·NCT06942767·100 enrolled

Extensive-stage Small-cell Lung Cancer1 trial

A Phase III, Randomized, Controlled, Open-label Clinical Study to Compare the Efficacy and Safety of QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy as First-line Treatment in Participants With Extensive-stage Small Cell Lung Cancer

Recruiting·Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07802821·556 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

A Randomized, Double-Blind, Multicenter, Pharmacokinetic Equivalence Clinical Trial of QL2107 (Keytruda® Biosimilar Candidate) in Comparison With Keytruda® (Pembrolizumab) for Adjuvant Therapy to Demonstrate Pharmacokinetic Similarity in Subjects With Resected Non-Small Cell Lung Cancer

Active, not recruiting·Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT07162883·146 enrolled

Details

Drug Info

Related News